Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reflux Disease, Gastro-Esophageal Clear all
Completed Phase 3 Interventional

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

NCT00214552
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
rabeprazole
Drug
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Richland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 3 Interventional

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophagitis
Interventions
Pantoprazole for approximately 9 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Jun 10, 2026, 7:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance in Pediatric Population

NCT02320981
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
Interventions
Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 18 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

NCT00373334
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Heartburn
Interventions
nizatidine (axid), placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
30 Days to 1 Year
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Jun 10, 2026, 7:27 PM EDT
Completed No phase listed Observational

RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol

NCT01406210
View directory record Official record
Conditions
Reflux, Gastroesophageal Reflux Disease (GERD)
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
16 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

NCT00307944
View directory record Official record
Conditions
Acid Reflux Disease, Obstructive Sleep Apnea
Interventions
Pantoprazole
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jun 10, 2026, 7:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cromolyn Detection of Silent Aspiration

NCT01841307
View directory record Official record
Conditions
Gastroesophageal Reflux, Respiratory Aspiration, Idiopathic Pulmonary Fibrosis, Lung Transplantation
Interventions
Cromolyn Sodium
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

NCT00627016
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Jun 10, 2026, 7:27 PM EDT
Active, not recruiting No phase listed Observational

Gastric Ultrasound for Estimation of the Aspiration Risk Study

NCT03310528
View directory record Official record
Conditions
Respiratory Aspiration of Gastric Contents
Interventions
Interview questionnaire, Gastric ultrasound exam
Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

NCT00287391
View directory record Official record
Conditions
Insomnia, GERD
Interventions
Rabeprazole
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2007 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Not applicable Interventional

Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures

NCT01260935
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophageal Reflux, Gastroesophageal Reflux Disease, GERD
Interventions
Laparoscopic Hill Repair, Laparoscopic Nissen Repair
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jun 10, 2026, 7:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry

NCT00574327
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

NCT00855361
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 44 Weeks
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants

NCT00131248
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Metaclopramide, Ranitidine, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Month to 6 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?

NCT02226484
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Acid Reflux, Reflux
Interventions
Quercetin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Jun 10, 2026, 7:27 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 10, 2026, 7:27 PM EDT
Active, not recruiting Not applicable Interventional

Gracie Diet for Gastroesophageal Reflux Disease

NCT04360252
View directory record Official record
Conditions
Gastroesophageal Reflux, GERD
Interventions
Gracie Diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jun 10, 2026, 7:27 PM EDT
Completed No phase listed Observational

Epidemiology of Barrett's Esophagus: A Population Based Study

NCT01286155
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Olmsted County Resident
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Jun 10, 2026, 7:27 PM EDT
Completed Not applicable Interventional Results available

Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

NCT02930824
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 100 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jun 10, 2026, 7:27 PM EDT
Completed No phase listed Observational

A Post-Approval Study of the LINX® Reflux Management System

NCT01940185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
LINX device
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 10, 2026, 7:27 PM EDT